ライフサイエンスコーパス: idiopathic pulmonary fibrosis

1 system diseases including asthma, COPD, and idiopathic pulmonary fibrosis.

2 scopic cryobiospy sample from a patient with idiopathic pulmonary fibrosis.

3 es longitudinal changes in lungs affected by idiopathic pulmonary fibrosis.

4 nic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis.

5 pected nonspecific interstitial pneumonia or idiopathic pulmonary fibrosis.

6 t human monoclonal antibody against CTGF, in idiopathic pulmonary fibrosis.

7 eir relationship with disease progression in idiopathic pulmonary fibrosis.

8 ease, and interstitial lung diseases such as idiopathic pulmonary fibrosis.

9 as a diagnostic and prognostic biomarker of idiopathic pulmonary fibrosis.

10 cause of the fibrotic changes that underlie idiopathic pulmonary fibrosis.

11 reatment options available for patients with idiopathic pulmonary fibrosis.

12 ated in fibroblasts from human subjects with idiopathic pulmonary fibrosis.

13 was also induced in myofibroblasts in human idiopathic pulmonary fibrosis.

14 dyskeratosis congenita, aplastic anemia, and idiopathic pulmonary fibrosis.

15 idiopathic cases of organ fibrosis, such as idiopathic pulmonary fibrosis.

16 e response play roles in the pathogenesis of idiopathic pulmonary fibrosis.

17 em cells (LR-MSC) plays an important role in idiopathic pulmonary fibrosis.

18 were not correlated with disease severity of idiopathic pulmonary fibrosis.

19 RNA-related collagen V overexpression during idiopathic pulmonary fibrosis.

20 there is consideration of their use to treat idiopathic pulmonary fibrosis.

21 as chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.

22 proves the feasibility of clinical trials in idiopathic pulmonary fibrosis.

23 interstitial lung diseases, particularly for idiopathic pulmonary fibrosis.

24 n clinical trials and to guide management of idiopathic pulmonary fibrosis.

25 tween healthy controls and participants with idiopathic pulmonary fibrosis.

26 ration of two new drugs for the treatment of idiopathic pulmonary fibrosis.

27 s, thus avoiding surgery in the diagnosis of idiopathic pulmonary fibrosis.

28 ng inflammation characteristic of asthma and idiopathic pulmonary fibrosis.

29 or of or against treatment interventions for idiopathic pulmonary fibrosis.

30 of scar tissue in the lungs of patients with idiopathic pulmonary fibrosis.

31 s a novel, safe, and effective treatment for idiopathic pulmonary fibrosis.

32 r of response to nintedanib in patients with idiopathic pulmonary fibrosis.

33 could slow, stop, or reverse progression of idiopathic pulmonary fibrosis.

34 ll (AEC2) dysfunction in the pathogenesis of idiopathic pulmonary fibrosis.

35 5 patients), following acute exacerbation of idiopathic pulmonary fibrosis.

36 re upregulated in samples from patients with idiopathic pulmonary fibrosis.

37 pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis.

38 oblasts of fibrotic lungs from patients with idiopathic pulmonary fibrosis.

39 nuclear cell (PBMC) samples of patients with idiopathic pulmonary fibrosis.

40 ed as potential targets for the treatment of idiopathic pulmonary fibrosis.

41 onse to pro-fibrotic stimuli, which fails in idiopathic pulmonary fibrosis.

42 ontinuation of nintedanib was progression of idiopathic pulmonary fibrosis (51 [12%] patients continu

43 In idiopathic pulmonary fibrosis, a fatal form of progressi

44 ncological indications and diseases, such as idiopathic pulmonary fibrosis, a number may hold promise

45 Idiopathic pulmonary fibrosis, a progressive and inevita

46 ronic obstructive pulmonary disease, asthma, idiopathic pulmonary fibrosis, acute respiratory distres

47 transplant (aHR, 1.3; 95% CI, 1.0-1.7), and idiopathic pulmonary fibrosis (aHR, 1.4; 95% CI, 1.0-1.8

48 ently used to inhibit TGF-beta signalling in idiopathic pulmonary fibrosis, ameliorated BK dysfunctio

49 f two effective treatments for patients with idiopathic pulmonary fibrosis, an accurate diagnosis is

50 in the lung tissues from both patients with idiopathic pulmonary fibrosis and a mouse model of bleom

51 l dysfunction and apoptosis are important in idiopathic pulmonary fibrosis and asbestosis.

52 elevated in lung biopsies from patients with idiopathic pulmonary fibrosis and bleomycin (BLM)-induce

53 disorders, including dyskeratosis congenita, idiopathic pulmonary fibrosis and bone marrow failure.

54 ought to contribute towards diseases such as idiopathic pulmonary fibrosis and chronic obstructive pu

55 ribute to EMT, ATII cells from patients with idiopathic pulmonary fibrosis and chronic obstructive pu

56 ed vasculitis, systemic lupus erythematosus, idiopathic pulmonary fibrosis and dengue haemorrhagic fe

57 itoring disease progression in patients with idiopathic pulmonary fibrosis and emphysema extent great

58 RATIONALE: Patients with idiopathic pulmonary fibrosis and emphysema may have art

59 tation in lung disease that is recognized as idiopathic pulmonary fibrosis and emphysema.

60 erstitial pneumonia pattern is a hallmark of idiopathic pulmonary fibrosis and is essential for its d

61 ibrotic areas of lungs of both patients with idiopathic pulmonary fibrosis and mice that are subjecte

62 nto the clinical assessment of patients with idiopathic pulmonary fibrosis and other fibrotic disorde

63 ge-scale real applications in breast cancer, idiopathic pulmonary fibrosis and pan-cancer methylation

64 Patients with idiopathic pulmonary fibrosis and percentage of predicte

65 In patients with idiopathic pulmonary fibrosis and preserved lung functio

66 uencing of human lungs, including those from idiopathic pulmonary fibrosis and scleroderma patients,

67 tors of disease progression in patients with idiopathic pulmonary fibrosis and the effect of nintedan

68 Pamrevlumab attenuated progression of idiopathic pulmonary fibrosis and was well tolerated.

69 h 31, 2012, 189 had a confirmed diagnosis of idiopathic pulmonary fibrosis and were included in subse

70 Rett syndrome, inherited retinal disorders, idiopathic pulmonary fibrosis, and Charcot-Marie-Tooth d

71 onic renal disease, heart failure, diabetes, idiopathic pulmonary fibrosis, and scleroderma.

72 s of chronic diseases such as severe asthma, idiopathic pulmonary fibrosis, and systemic sclerosis.

73 onsible for collagen V overexpression during idiopathic pulmonary fibrosis, and these miRNAs may serv

74 tolerability of nintedanib in patients with idiopathic pulmonary fibrosis, and this was analysed in

75 Conclusions: Among patients with idiopathic pulmonary fibrosis, antifibrotic agents may b

76 atrix (ECM) turnover predicts progression of idiopathic pulmonary fibrosis as determined by change in

77 e up-regulated in the lungs of patients with idiopathic pulmonary fibrosis as well as in wound healin

78 ession, in telomere-related diseases such as idiopathic pulmonary fibrosis, as well as in mice and ot

79 irfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis (ASCEND 016; 52 weeks)-for

80 database, we identified 8,098 patients with idiopathic pulmonary fibrosis between October 1, 2014 an

81 biomarkers to better stratify patients with idiopathic pulmonary fibrosis by risk for lung transplan

82 in serum and lung tissue from patients with idiopathic pulmonary fibrosis compared to healthy volunt

83 e increased in the serum of individuals with idiopathic pulmonary fibrosis compared with healthy cont

84 Idiopathic pulmonary fibrosis comprised 34% with idiopat

85 specific immune cell type from patients with idiopathic pulmonary fibrosis could identify those at hi

86 Patients with idiopathic pulmonary fibrosis could use nintedanib over

87 ns were related to subsequent progression of idiopathic pulmonary fibrosis (defined as death or decli

88 ative to control participants, patients with idiopathic pulmonary fibrosis demonstrate excessive mono

89 -onset ILD in India, followed by CTD-ILD and idiopathic pulmonary fibrosis; diagnoses varied between

90 dyskeratosis congenita, aplastic anemia, and idiopathic pulmonary fibrosis disrupt the binding betwee

91 d the apoptotic susceptibility of normal and idiopathic pulmonary fibrosis fibroblasts; blocked TGF-b

92 Drug Administration (FDA)-approved drug for idiopathic pulmonary fibrosis, for its therapeutic effec

93 profiled monocyte counts in 45 patients with idiopathic pulmonary fibrosis from March 12, 2010, to Ma

94 Secondary analysis distinguished idiopathic pulmonary fibrosis from non-idiopathic pulmon

95 d a pooled cohort study of 517 patients with idiopathic pulmonary fibrosis from three IPFnet multicen

96 as similar to that observed in patients with idiopathic pulmonary fibrosis; gastrointestinal adverse

97 placebo-controlled trials of IFN-gamma-1b in idiopathic pulmonary fibrosis (GIPF-001 [NCT00047645] an

98 an FDA approved anti-fibrotic drug to treat idiopathic pulmonary fibrosis, has been shown to amelior

99 ished idiopathic pulmonary fibrosis from non-idiopathic pulmonary fibrosis ILD and used lung function

100 e, 48.1% air coolers), CTD-ILD in 13.9%, and idiopathic pulmonary fibrosis in 13.7%.

101 n for transplantation at index operation was idiopathic pulmonary fibrosis in 8 of 10 patients (1.2%

102 Patients with idiopathic pulmonary fibrosis in a clinical trial of pre

103 esults using PBMC samples from patients with idiopathic pulmonary fibrosis in two independent cohorts

104 We analyzed the first 200 hits for "idiopathic pulmonary fibrosis" in Google, Yahoo, and Bin

105 pplying the concept of precision medicine to idiopathic pulmonary fibrosis, in particular to search f

106 h fibrosing ILD, including 456 patients with idiopathic pulmonary fibrosis (IPF) (men, 366; women, 90

107 Despite shared environmental exposures, idiopathic pulmonary fibrosis (IPF) and chronic obstruct

108 ) cause telomere diseases including familial idiopathic pulmonary fibrosis (IPF) and dyskeratosis con

109 Cough can be a debilitating symptom of idiopathic pulmonary fibrosis (IPF) and is difficult to

110 interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF) and sarcoidosis.

111 ious cause, such as the devastating diseases idiopathic pulmonary fibrosis (IPF) and scleroderma.

112 nal changes in a cohort of participants with idiopathic pulmonary fibrosis (IPF) and to evaluate the

113 or the computed tomographic (CT) features of idiopathic pulmonary fibrosis (IPF) and to gain insight

114 Rationale: Several new drugs for idiopathic pulmonary fibrosis (IPF) are in development.

115 ry-related hospitalizations of patients with idiopathic pulmonary fibrosis (IPF) are more frequent th

116 Acute lung injury (ALI) and idiopathic pulmonary fibrosis (IPF) are severe lung dise

117 nic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) are two pathological

118 lung injury is related to poor outcome, and idiopathic pulmonary fibrosis (IPF) can be regarded as a

119 Patients with idiopathic pulmonary fibrosis (IPF) can experience life-

120 Rationale: Idiopathic pulmonary fibrosis (IPF) causes considerable

121 rom the lungs of the patients suffering from idiopathic pulmonary fibrosis (IPF) exhibit enhanced FXI

122 Fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) exhibited an increas

123 Idiopathic pulmonary fibrosis (IPF) has a poor prognosis

124 e, several large registries of patients with idiopathic pulmonary fibrosis (IPF) have been establishe

125 nic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF) have contrasting cli

126 urgical lung biopsy, patients diagnosed with idiopathic pulmonary fibrosis (IPF) in clinical practice

127 lcysteine) is used with pirfenidone to treat idiopathic pulmonary fibrosis (IPF) in Europe.

128 dysfunctional telomeres are at the origin of idiopathic pulmonary fibrosis (IPF) in patients mutant f

129 ciated with adverse events for patients with idiopathic pulmonary fibrosis (IPF) in the PANTHER-IPF (

130 RATIONALE: Idiopathic pulmonary fibrosis (IPF) involves the accumul

131 Idiopathic pulmonary fibrosis (IPF) is a chronic age-rel

132 Idiopathic pulmonary fibrosis (IPF) is a chronic and fat

133 RATIONALE: Idiopathic pulmonary fibrosis (IPF) is a chronic fatal l

134 Idiopathic pulmonary fibrosis (IPF) is a chronic progres

135 Idiopathic pulmonary fibrosis (IPF) is a chronic progres

136 Idiopathic pulmonary fibrosis (IPF) is a chronic progres

137 Idiopathic pulmonary fibrosis (IPF) is a chronic, progre

138 Idiopathic pulmonary fibrosis (IPF) is a chronic, progre

139 Idiopathic pulmonary fibrosis (IPF) is a common, progres

140 Rationale: Idiopathic pulmonary fibrosis (IPF) is a complex lung di

141 Idiopathic pulmonary fibrosis (IPF) is a deadly chronic

142 Rationale: Idiopathic pulmonary fibrosis (IPF) is a deadly disease

143 Idiopathic pulmonary fibrosis (IPF) is a devastating and

144 Idiopathic pulmonary fibrosis (IPF) is a devastating dis

145 Idiopathic pulmonary fibrosis (IPF) is a devastating dis

146 Idiopathic pulmonary fibrosis (IPF) is a devastating lun

147 Idiopathic pulmonary fibrosis (IPF) is a devastating lun

148 Rationale: Idiopathic pulmonary fibrosis (IPF) is a devastating pro

149 Idiopathic pulmonary fibrosis (IPF) is a disease charact

150 Idiopathic Pulmonary Fibrosis (IPF) is a disease with a

151 Idiopathic pulmonary fibrosis (IPF) is a disease with hi

152 Idiopathic pulmonary fibrosis (IPF) is a fatal and incur

153 Idiopathic pulmonary fibrosis (IPF) is a fatal disease c

154 Idiopathic pulmonary fibrosis (IPF) is a fatal disease o

155 Idiopathic pulmonary fibrosis (IPF) is a fatal disease w

156 Idiopathic pulmonary fibrosis (IPF) is a fatal lung dise

157 Idiopathic pulmonary fibrosis (IPF) is a form of progres

158 Idiopathic pulmonary fibrosis (IPF) is a lethal, chronic

159 Idiopathic pulmonary fibrosis (IPF) is a lethal, fibropr

160 Idiopathic pulmonary fibrosis (IPF) is a lung parenchyma

161 Idiopathic pulmonary fibrosis (IPF) is a progressive and

162 Idiopathic pulmonary fibrosis (IPF) is a progressive and

163 Idiopathic pulmonary fibrosis (IPF) is a progressive and

164 Idiopathic pulmonary fibrosis (IPF) is a progressive and

165 Idiopathic pulmonary fibrosis (IPF) is a progressive cli

166 Idiopathic pulmonary fibrosis (IPF) is a progressive dis

167 Idiopathic pulmonary fibrosis (IPF) is a progressive dis

168 Idiopathic pulmonary fibrosis (IPF) is a progressive fib

169 Idiopathic pulmonary fibrosis (IPF) is a progressive int

170 Idiopathic pulmonary fibrosis (IPF) is a progressive lun

171 Idiopathic pulmonary fibrosis (IPF) is a progressive lun

172 Idiopathic pulmonary fibrosis (IPF) is a progressive par

173 Idiopathic pulmonary fibrosis (IPF) is a progressive, fa

174 Idiopathic pulmonary fibrosis (IPF) is a progressive, fa

175 Idiopathic pulmonary fibrosis (IPF) is a rare and devast

176 Idiopathic pulmonary fibrosis (IPF) is a severe form of

177 Idiopathic pulmonary fibrosis (IPF) is an age-related di

178 RATIONALE: Idiopathic pulmonary fibrosis (IPF) is an increasingly r

179 Idiopathic pulmonary fibrosis (IPF) is characterized by

180 Idiopathic pulmonary fibrosis (IPF) is characterized by

181 dels; however, the role of these proteins in idiopathic pulmonary fibrosis (IPF) is not known.

182 (ILD), the risk among relatives of sporadic idiopathic pulmonary fibrosis (IPF) is not known.Objecti

183 Idiopathic pulmonary fibrosis (IPF) is progressive and r

184 The clinical course of idiopathic pulmonary fibrosis (IPF) is unpredictable.

185 yofibroblastic differentiation of normal and idiopathic pulmonary fibrosis (IPF) lung fibroblasts.

186 EVERBalpha expression was increased in human idiopathic pulmonary fibrosis (IPF) lung tissue.

187 Patients with idiopathic pulmonary fibrosis (IPF) often experience pre

188 rs, individuals might be diagnosed as having idiopathic pulmonary fibrosis (IPF) or chronic (fibrotic

189 In this exploratory analysis, adults with idiopathic pulmonary fibrosis (IPF) or chronic obstructi

190 es in the lung microbial community influence idiopathic pulmonary fibrosis (IPF) progression.

191 propriate clinical setting, the diagnosis of idiopathic pulmonary fibrosis (IPF) requires a pattern o

192 geal reflux (GER) is higher in patients with idiopathic pulmonary fibrosis (IPF) than in matched cont

193 Patients with idiopathic pulmonary fibrosis (IPF) treated with PRM-151

194 significance of a first-choice diagnosis of idiopathic pulmonary fibrosis (IPF) versus not IPF for M

195 Idiopathic pulmonary fibrosis (IPF), a chronic and progr

196 ulum (ER) stress in AEC has been observed in idiopathic pulmonary fibrosis (IPF), a disease of aging.

197 The progression and severity of idiopathic pulmonary fibrosis (IPF), a fatal and irrever

198 Rationale: The relevance of hormones in idiopathic pulmonary fibrosis (IPF), a predominantly mal

199 believed to contribute to the development of Idiopathic Pulmonary Fibrosis (IPF), a progressive and f

200 gs of human donors and patients with COPD or idiopathic pulmonary fibrosis (IPF), as well as in cigar

201 ides an updated approach to the diagnosis of idiopathic pulmonary fibrosis (IPF), based on a systemat

202 Mortality prediction is well studied in idiopathic pulmonary fibrosis (IPF), but little is known

203 BAL of patients with stable and progressive idiopathic pulmonary fibrosis (IPF), defined as <5% and

204 Pathogenic fibrotic diseases, including idiopathic pulmonary fibrosis (IPF), have some of the wo

205 are effective in slowing the progression of idiopathic pulmonary fibrosis (IPF), it remains a debili

206 iven the paucity of effective treatments for idiopathic pulmonary fibrosis (IPF), new insights into t

207 Although aging is a known risk factor for idiopathic pulmonary fibrosis (IPF), the pathogenic mech

208 In Idiopathic Pulmonary Fibrosis (IPF), there is unrelentin

209 expressed in lung tissues from patients with idiopathic pulmonary fibrosis (IPF), whereas PIAS4 prote

210 trol (fibrosis-free) donors or patients with idiopathic pulmonary fibrosis (IPF), which is a very agg

211 re the genetic risk architecture observed in idiopathic pulmonary fibrosis (IPF), with key risk facto

212 a key therapeutic strategy in patients with idiopathic pulmonary fibrosis (IPF).

213 that underlies chronic lung diseases such as idiopathic pulmonary fibrosis (IPF).

214 ave identified rs2076295 in association with idiopathic pulmonary fibrosis (IPF).

215 tribute to the initiation and progression of idiopathic pulmonary fibrosis (IPF).

216 each been implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF).

217 ing and is implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF).

218 gy of diffuse parenchymal diseases including idiopathic pulmonary fibrosis (IPF).

219 e are associated with disease progression in idiopathic pulmonary fibrosis (IPF).

220 agen deposition in fibrotic diseases such as idiopathic pulmonary fibrosis (IPF).

221 plays a crucial role in the pathogenesis of idiopathic pulmonary fibrosis (IPF).

222 s of human subjects with rapidly progressive idiopathic pulmonary fibrosis (IPF).

223 be the critical link to the pathogenesis of idiopathic pulmonary fibrosis (IPF).

224 r a confident multidisciplinary diagnosis of idiopathic pulmonary fibrosis (IPF).

225 actor for the development and progression of idiopathic pulmonary fibrosis (IPF).

226 thereby contributing to the pathogenesis of idiopathic pulmonary fibrosis (IPF).

227 patients with the debilitating lung disease idiopathic pulmonary fibrosis (IPF).

228 , has been implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF).

229 efforts to identify effective therapies for idiopathic pulmonary fibrosis (IPF).

230 n's nodules and also in the fibrotic foci of idiopathic pulmonary fibrosis (IPF).

231 elaxin is considered a potential therapy for idiopathic pulmonary fibrosis (IPF).

232 n in multiple fibrotic conditions, including idiopathic pulmonary fibrosis (IPF).

233 diator that is pivotal to the development of idiopathic pulmonary fibrosis (IPF).

234 linical trial of inhaled CO in patients with idiopathic pulmonary fibrosis (IPF).

235 osecretory dysfunction to the development of idiopathic pulmonary fibrosis (IPF).Objectives: We sough

236 ated with the highest genetic risk locus for idiopathic pulmonary fibrosis (IPF); however, the extent

237 y has been implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF); however, the repert

238 Idiopathic pulmonary fibrosis is a chronic, progressive

239 Idiopathic pulmonary fibrosis is a deadly disease charac

240 Idiopathic pulmonary fibrosis is a devastating disease,

241 Idiopathic pulmonary fibrosis is a devastating lung dise

242 Idiopathic pulmonary fibrosis is a devastating lung dise

243 Idiopathic pulmonary fibrosis is a disease characterized

244 Idiopathic pulmonary fibrosis is a fatal disease involvi

245 Idiopathic pulmonary fibrosis is a fatal lung disease wi

246 Idiopathic pulmonary fibrosis is a progressive scarring

247 Idiopathic pulmonary fibrosis is a prototype of chronic,

248 A hallmark of idiopathic pulmonary fibrosis is the excess accumulation

249 The relevance of precision medicine to idiopathic pulmonary fibrosis is yet to be established,

250 Idiopathic pulmonary fibrosis lung alveolar type II cell

251 Normal and idiopathic pulmonary fibrosis lung fibroblasts were trea

252 Human idiopathic pulmonary fibrosis lung myofibroblasts expres

253 by both mesothelial and mesenchymal cells in idiopathic pulmonary fibrosis lungs but has limited or n

254 d evidence for increased AECII senescence in idiopathic pulmonary fibrosis lungs, suggesting potentia

255 Idiopathic pulmonary fibrosis may be associated with inc

256 f patients with PVOD (n = 19), PAH (n = 20), idiopathic pulmonary fibrosis (n = 13), and chronic obst

257 ficantly higher in patients with progressive idiopathic pulmonary fibrosis (n=32) than in those with

258 fibrosis (n=71) than in patients with stable idiopathic pulmonary fibrosis (n=60) by 6 months.

259 ficantly higher in patients with progressive idiopathic pulmonary fibrosis (n=71) than in patients wi

260 uded ACE-IPF (Anticoagulant Effectiveness in Idiopathic Pulmonary Fibrosis) (n = 101) and an independ

261 ts are now available for adult patients with idiopathic pulmonary fibrosis, no clinical trials have b

262 open surgery, and a provisional diagnosis of idiopathic pulmonary fibrosis or connective tissue disea

263 al cohort study (PROFILE), participants with idiopathic pulmonary fibrosis or idiopathic non-specific

264 e (PAF, 14%); chronic bronchitis (PAF, 13%); idiopathic pulmonary fibrosis (PAF, 26%); hypersensitivi

265 s upregulated in peripheral blood cells from idiopathic pulmonary fibrosis patients and correlated wi

266 In lung tissue from idiopathic pulmonary fibrosis patients, a strong up-regu

267 ers can also detect fibrotic lung disease in idiopathic pulmonary fibrosis patients.

268 valuated in an exploratory phase 2a study in idiopathic pulmonary fibrosis patients.

269 5 and miR-186 were decreased in the lungs of idiopathic pulmonary fibrosis patients.

270 f bleomycin-treated mice and in the lungs of idiopathic pulmonary fibrosis patients.

271 Many patients with suspected idiopathic pulmonary fibrosis present with atypical high

272 Importantly, in a mouse model of idiopathic pulmonary fibrosis (RAGE-/-), reconstitution

273 In clinical trials of idiopathic pulmonary fibrosis, rates of all-cause mortal

274 R84, currently a target for the treatment of idiopathic pulmonary fibrosis, recent times have seen th

275 d mortality (0.0237), and treatment-emergent idiopathic-pulmonary-fibrosis-related (0.0132) mortality

276 ent-emergent all-cause mortality (p=0.0420), idiopathic-pulmonary-fibrosis-related mortality (0.0237)

277 0.35 [0.17-0.72; 0.0029]; treatment-emergent idiopathic-pulmonary-fibrosis-related mortality 0.32 [0.

278 ll-cause mortality 0.45 [0.24-0.83; 0.0094]; idiopathic-pulmonary-fibrosis-related mortality 0.35 [0.

279 is-related mortality, and treatment-emergent idiopathic-pulmonary-fibrosis-related mortality at weeks

280 ity, treatment-emergent all-cause mortality, idiopathic-pulmonary-fibrosis-related mortality, and tre

281 -myofibroblast differentiation/activation in idiopathic pulmonary fibrosis remain poorly understood.

282 and fibroblasts have long been the focus of idiopathic pulmonary fibrosis research, the role of vari

283 bo-Clinical Studies Assessing Pirfenidone in Idiopathic Pulmonary Fibrosis: Research of Efficacy and

284 sis of medical records of 7459 patients with idiopathic pulmonary fibrosis showed that patients with

285 ical Markers to Estimate Time-Progression in Idiopathic Pulmonary Fibrosis) study were used to conduc

286 ro-fibrotic responses in a cellular model of idiopathic pulmonary fibrosis, supporting the potential

287 health records (EHR) of 45 068 patients with idiopathic pulmonary fibrosis, systemic sclerosis, hyper

288 TH, were higher in lungs from patients with idiopathic pulmonary fibrosis than in control individual

289 24) at baseline were higher in patients with idiopathic pulmonary fibrosis than in healthy controls.

290 hort telomere syndromes manifest as familial idiopathic pulmonary fibrosis; they are the most common

291 n American Thoracic Association guideline on idiopathic pulmonary fibrosis treatment.

292 irfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis] trial), including all pat

293 radiation-induced pulmonary fibrosis and in idiopathic pulmonary fibrosis, two diseases considered t

294 In a study of idiopathic pulmonary fibrosis, we reverse a paradoxical

295 tyrosine kinase inhibitor, in patients with idiopathic pulmonary fibrosis were assessed in two phase

296 as shortened telomeres are risk factors for idiopathic pulmonary fibrosis, where repetitive injury t

297 ndpoint for clinical trials in patients with idiopathic pulmonary fibrosis who have mild-to-moderate

298 In the Yale cohort, 15 patients with idiopathic pulmonary fibrosis (with five healthy control

299 ntrolled trial, patients with a diagnosis of idiopathic pulmonary fibrosis within the past 3 years an

300 research is to develop a method to diagnose idiopathic pulmonary fibrosis without the patient having